RAD51AP1 and glioblastoma: Similarly, as also stated by Wang et al. [81], the discovery of RAD51AP1 as an oncogene in EGFRvIII-driven GBM opens new avenues for combination therapies, such as temozolomide with RAD51AP1 inhibition, which could enhance treatment efficacy and improve patient outcomes.